SCHEMBL6158906

SCHEMBL6158906

CCOC(=O)CCSC1CC(=O)N(Cc2ccc(Oc3ccccc3)cc2)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
GAA P10253 3/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
CCR8 P51685 1/20 0.40
ADAM17 P78536 1/20 0.39
HCRTR1 O43613 2/20 0.39
HCRTR2 O43614 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
STAT6 P42226 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6159152 0.83 ALDH1A1 (0.50) ALDH1A1NPSR1KMT2ATDP1GAA
SCHEMBL6158537 0.80 HCRTR2 (0.50) KMT2AGAACCR8ADAM17HCRTR1
SCHEMBL6158601 0.79 ALDH1A1 (0.48) ALDH1A1NPSR1KMT2ATDP1GAA
SCHEMBL6158988 0.79 ALDH1A1 (0.53) ALDH1A1NPSR1KMT2ATDP1GAA
SCHEMBL6157032 0.78 ALDH1A1 (0.54) ALDH1A1NPSR1KMT2ATDP1GAA
SCHEMBL6158480 0.76 ALDH1A1 (0.47) ALDH1A1NPSR1KMT2ATDP1GAA
SCHEMBL6159352 0.74 HCRTR2 (0.48) ALDH1A1KMT2AGAACCR8ADAM17
SCHEMBL6159078 0.71 MEN1 (0.45) ALDH1A1KMT2AHPGDLMNAHCRTR1
SCHEMBL6164828 0.71 MT-CO2 (0.53) ALDH1A1KMT2AGAAHPGDHSD17B10
SCHEMBL6158680 0.71 HCRTR1 (0.46) ALDH1A1NPSR1HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1357123-B1 Novel carbapenem, medical and antibacterial comprisisng the same, and uses thereof SUMITOMO PHARMA (JP) 2005-11-30 EP disclosed
US-6953789-B2 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-10-11 US disclosed
US-20040157894-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
US-6699881-B2 MATRIX METALLOPROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-02 US disclosed
US-20030078253-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2003-04-24 US disclosed
US-6420415-B1 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-16 US disclosed
EP-1132379-A1 NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078253-A1 Thiol compounds, their production and use TST, QSOX1, SULT1E1 ALDH1A1 905/4885NPSR1 1036/4885KMT2A 1898/4885
US-20040157894-A1 Thiol compounds, their production and use TST, SULT1E1, QSOX1 ALDH1A1 877/4885NPSR1 1120/4885KMT2A 1850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.